Nanocellulose-Based Nanoporous Filter Paper for Virus Removal Filtration of Human Intravenous Immunoglobulin
Source abstract
Abstract
Human intravenous immunoglobulin (IVIG) is a highly valuable plasma-derived biotherapeutic with several important clinical indications in primary and acquired immunodeficiencies as well as autoimmune diseases, especially neuropathies. Ensuring the viral safety of plasma-derived products, such as human IVIG, is mandatory. Viral filtration is commonly used to affect viral removal in the manufacture of plasma products. Viral filtration of large volumes of a IVIG feed solution can take significant time, the required filter area can be large, and the resultant total cost of filtration is considerable. Therefore, there is a need for a high-capacity filter, which can process large volumes of plasma-derived biotherapeutic products within a short time at reduced cost. Here, we describe for the first time the performance of a nanocellulose-based virus removal filter paper in the processing of human IVIG, which has the potential to address the above-stated issues. The filter exhibited 5–6 log virus clearance of ΦX174 (28 nm; pI 6.6) or MS2 (27 nm; pI 3.9) phages during the filtration of spiked IVIG solutions (11 mg/mL, pH 4.9). To simulate real-life production conditions, filtration at 288 L/m2, corresponding to 3 kg of protein/m2, at 3 bar was undertaken. No substantial filter fouling was evident, with the flux remaining stable throughout filtration at 20–30 L/m2·h. The predicted volumetric capacity Vmax was ≥1700 L/m2, which corresponds to the processing of ≥19 kg/m2 of immunoglobulins. A number of characterization tests encompassing size-exclusion high-pressure liquid chromatography, dynamic light scattering, and polyacrylamide gel electrophoresis confirmed immunoglobulin integrity before and after filtration. This study has shown that a mille-feuille filter paper manufacturing process offers the possibility of producing cost-efficient viral removal filters with the required performance capabilities suitable for the processing of plasma-derived immunoglobulins and recombinant monoclonal antibodies.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Immunodeficiency and Autoimmune Disorders · Parvovirus B19 Infection Studies · Platelet Disorders and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Nanotechnology and Functional Materials, Department of Engineering Sciences, Uppsala University, Box 534, 751 21 Uppsala, Sweden
Funding
Vetenskapsr?det · Knut och Alice Wallenbergs Stiftelse · H2020 European Institute of Innovation and Technology · Chinese Academy of Sciences
References (34)
Show source-provided references
1. 10.1016/j.tips.2004.04.00210.1016/j.tips.2004.04.002 ↗
2. 10.4049/jimmunol.170127110.4049/jimmunol.1701271 ↗
3. Agency, E. M. Guideline core SmPc human normal immunoglobulin intravenous administration IvIg.EMA/CHMP/BPWP/94038/2007, revision 5; 2018.
4. 10.3389/fimmu.2014.0066510.3389/fimmu.2014.00665 ↗
5. 10.2146/ajhp05028210.2146/ajhp050282 ↗
6. 10.2146/ajhp07058210.2146/ajhp070582 ↗
7. 10.1038/nri340110.1038/nri3401 ↗
8. 10.1385/CRIAI:29:3:33310.1385/CRIAI:29:3:333 ↗
9. 10.1331/10865800276331688810.1331/108658002763316888 ↗
10. WHO Expert Committee on Biological Standardization; World Health Organisation: Geneva, Switzerland, 2004.
11. 10.1002/biot.20050003710.1002/biot.200500037 ↗
12. Buchacher A. · 2013 · 18510.1002/9781118356807.ch13 ↗
13. Quality of Biotechnological Products: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin.CPMP/ICH/295/95; European Medicines Agency, 1995.
14. Technical Report No. 41: Virus Filtration; PDA, 2005; pp 1–42.10.1016/S0015-1882(05)70732-1 ↗
15. 10.1002/jps.2388110.1002/jps.23881 ↗
16. 10.1016/j.memsci.2005.10.05710.1016/j.memsci.2005.10.057 ↗
17. 10.1016/j.biologicals.2010.02.00810.1016/j.biologicals.2010.02.008 ↗
18. 10.1007/s40259-017-0212-y10.1007/s40259-017-0212-y ↗
19. 10.1016/j.biologicals.2017.10.00610.1016/j.biologicals.2017.10.006 ↗
20. 10.1016/j.biologicals.2018.01.00410.1016/j.biologicals.2018.01.004 ↗
21. 10.1016/j.biologicals.2014.11.00510.1016/j.biologicals.2014.11.005 ↗
22. Bolton G. · BioPharm. International · 2004 · 17 · 38
23. 10.1002/adhm.20130064110.1002/adhm.201300641 ↗
24. 10.1039/C6MH00090H10.1039/C6MH00090H ↗
25. 10.1021/acsami.6b0309310.1021/acsami.6b03093 ↗
26. 10.1016/j.memsci.2018.11.00210.1016/j.memsci.2018.11.002 ↗
27. 10.1016/j.biologicals.2015.08.00110.1016/j.biologicals.2015.08.001 ↗
28. 10.1002/gch2.20180003110.1002/gch2.201800031 ↗
29. 10.1021/acs.langmuir.7b0056610.1021/acs.langmuir.7b00566 ↗
30. Badmington F. · Pharm. Technol. · 1995 · 19 · 64
31. 10.1016/j.tca.2005.02.01510.1016/j.tca.2005.02.015 ↗
32. Dedeo M. T. · 2011 · 103 · 353
33. 10.1111/j.1365-2672.2010.04663.x10.1111/j.1365-2672.2010.04663.x ↗
34. 10.1111/j.1423-0410.2009.01226.x10.1111/j.1423-0410.2009.01226.x ↗